Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 2/2017

01-02-2017 | Letter to the editor

Discrepancy between long-term and previously published analysis for osteonecrosis of the jaw under denosumab

Authors: Paul de Boissieu, Thierry Trenque

Published in: Supportive Care in Cancer | Issue 2/2017

Login to get access

Excerpt

Dear editor, …
Literature
1.
Stopeck AT, Fizazi K, Body JJ et al (2016) Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer 24:447–455CrossRefPubMed
2.
Fizazi K, Carducci M, Smith M et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813–822CrossRefPubMedPubMedCentral
3.
Stopeck AT, Lipton A, Body JJ et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132–5139CrossRefPubMed
4.
Metadata
Title
Discrepancy between long-term and previously published analysis for osteonecrosis of the jaw under denosumab
Authors
Paul de Boissieu
Thierry Trenque
Publication date
01-02-2017
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 2/2017
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3238-7

Other articles of this Issue 2/2017

Supportive Care in Cancer 2/2017 Go to the issue

Original Article

Cell adhesion molecules are altered during irinotecan-induced mucositis: a qualitative histopathological study

Review Article

Do-not-resuscitate orders in cancer patients: a review of literature

Original Article

Haematopoietic stem cell transplantation survivorship and quality of life: is it a small world after all?

Original Article

Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor

Original Article

The impact of a simplified documentation method for the Edmonton classification system for cancer pain (ECS-CP) on clinician utilization

Original Article

Evaluation of the effects and adverse drug reactions of low-dose dexamethasone premedication with weekly docetaxel
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits